Aplindore

Drug Profile

Aplindore

Alternative Names: DAB 452; Palindore; SLS-006; WAY-DAB 452

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Wyeth
  • Developer Ligand Pharmaceuticals; Wyeth
  • Class Antipsychotics; Indoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Parkinson's disease; Restless legs syndrome
  • Discontinued Schizophrenia

Most Recent Events

  • 22 Sep 2016 Aplindore sub-licensed to Seelos Therapeutics
  • 31 Dec 2011 Aplindore is available for licensing as of 31 Dec 2011. http://www.ligand.com/
  • 31 Dec 2009 Suspended - Phase-II for Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top